​

Neumora Therapeutics (NMRA) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

NMRA Stock Forecast

Neumora Therapeutics (NMRA) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $7.25, with a high of $8.00 and a low of $6.00. This represents a 255.39% increase from the last price of $2.04.

- $4 $8 $12 $16 $20 High: $8 Avg: $7.25 Low: $6 Last Closed Price: $2.04

NMRA Stock Rating

Neumora Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 5 Buy (62.50%), 1 Hold (12.50%), 2 Sell (25.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 2 1 5 Strong Sell Sell Hold Buy Strong Buy

NMRA Price Target Upside V Benchmarks

TypeNameUpside
StockNeumora Therapeutics255.39%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts245
Avg Price Target$7.00$7.25$6.20
Last Closing Price$2.04$2.04$2.04
Upside/Downside243.14%255.39%203.92%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 26232-18
Dec, 25133-18
Nov, 25223-18
Oct, 25214-18
Sep, 25215--8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 12, 2026Marc GoodmanLeerink Partners$8.00$2.27252.42%292.16%
Jan 05, 2026Graig SuvannavejhMizuho Securities$6.00$1.72248.84%194.12%
Dec 01, 2025RBC Capital$7.00$2.24212.50%243.14%
Oct 28, 2025Needham$8.00$2.60207.69%292.16%
Mar 07, 2025Stifel Nicolaus$2.00$1.4934.23%-1.96%
Jan 02, 2025Brian AbrahamsRBC Capital$4.00$1.97103.05%96.08%
Jul 22, 2024Ami FadiaNeedham$23.00$11.28103.90%1027.45%
Jul 08, 2024Graig SuvannavejhMizuho Securities$20.00$10.2595.12%880.39%
Jun 17, 2024Brian AbrahamsRBC Capital$29.00$9.71198.66%1321.57%
Mar 13, 2024Brian AbrahamsRBC Capital$31.00$14.81109.32%1419.61%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 01, 2025RBC CapitalSector PerformOutperformupgrade
Oct 28, 2025NeedhamBuyBuyhold
Oct 27, 2025GuggenheimNeutralBuyupgrade
Mar 07, 2025William BlairOutperformMarket Performdowngrade
Mar 07, 2025GuggenheimNeutraldowngrade
Jan 02, 2025RBC CapitalOutperformSector Performdowngrade
Oct 01, 2024H.C. WainwrightBuyinitialise
Jul 22, 2024NeedhamBuyinitialise
Jun 17, 2024RBC CapitalOutperformOutperformhold
Oct 10, 2023RBC CapitalOutperforminitialise

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.49$-1.53----
Avg Forecast$-1.75$-1.60$-1.61$-1.50$-1.19$-0.39
High Forecast$-0.95$-1.51$-1.16$-0.65$-0.65$-0.39
Low Forecast$-3.89$-1.62$-2.03$-2.08$-1.71$-0.39
Surprise %-14.86%-4.38%----

Revenue Forecast

$0 $90M $180M $270M $360M $450M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$34.26M$198.02M$420.29M
High Forecast---$34.28M$198.02M$420.29M
Low Forecast---$34.24M$198.02M$420.29M
Surprise %------

Net Income Forecast

$-650M $-530M $-410M $-290M $-170M $-50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-235.93M$-243.79M----
Avg Forecast$-235.93M$-248.33M$-287.92M$-302.80M$-223.81M$-62.47M
High Forecast$-151.23M$-239.66M$-184.30M$-102.87M$-103.42M$-62.47M
Low Forecast$-618.01M$-257.01M$-322.10M$-330.53M$-271.48M$-62.47M
Surprise %--1.83%----

NMRA Forecast FAQ

Is Neumora Therapeutics stock a buy?

Neumora Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 5 Buy, 1 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Neumora Therapeutics is a favorable investment for most analysts.

What is Neumora Therapeutics's price target?

Neumora Therapeutics's price target, set by 8 Wall Street analysts, averages $7.25 over the next 12 months. The price target range spans from $6 at the low end to $8 at the high end, suggesting a potential 255.39% change from the previous closing price of $2.04.

How does Neumora Therapeutics stock forecast compare to its benchmarks?

Neumora Therapeutics's stock forecast shows a 255.39% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Neumora Therapeutics over the past three months?

  • January 2026: 25.00% Strong Buy, 37.50% Buy, 25.00% Hold, 0% Sell, 12.50% Strong Sell.
  • December 2025: 12.50% Strong Buy, 37.50% Buy, 37.50% Hold, 0% Sell, 12.50% Strong Sell.
  • November 2025: 25.00% Strong Buy, 25.00% Buy, 37.50% Hold, 0% Sell, 12.50% Strong Sell.

What is Neumora Therapeutics’s EPS forecast?

Neumora Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.61, marking a 5.23% increase from the reported $-1.53 in 2024. Estimates for the following years are $-1.5 in 2026, $-1.19 in 2027, and $-0.39 in 2028.

What is Neumora Therapeutics’s revenue forecast?

Neumora Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $34.26M, followed by $198.02M for 2027, and $420.29M for 2028.

What is Neumora Therapeutics’s net income forecast?

Neumora Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-288M, representing an 18.10% increase from the reported $-244M in 2024. Projections indicate $-303M in 2026, $-224M in 2027, and $-62.473M in 2028.